Gaudium IVF and Women Health Limited has informed the Exchange about Investor Presentation
GAUDIUMIVF · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gaudium IVF reported strong FY26 consolidated revenue of Rs 10,435.70 Lakhs, up 47.6% YoY, driven by higher patient volumes across 7 hubs and 28 spokes pan-India. EBITDA margins compressed to 36.13% vs 40.48% in FY25, and PAT margin fell to 23.47% vs 27.12%, reflecting costs of scaling. The company listed on BSE & NSE in February 2026 after a Rs 90 Cr IPO, which reduced its Debt/Equity ratio sharply from 0.45 to 0.16. The company pioneered AI tools SiD and ERICA for sperm and embryo selection, claiming 58% first-attempt success rate and 85% for multiple attempts. Revenue split is 64% IVF Treatment, 31% Hospital, and 4% Pharmacy. The company has disclosed a three-year expansion roadmap targeting 3 new hubs in FY27, 8 new centers in FY28, and 1 more in FY29.
Strong revenue growth and IPO proceeds put the company in a solid financial position, but margin compression is a concern. The disclosed multi-year expansion plan signals growth intent but also raises capital deployment questions. Investors should monitor EBITDA margin recovery as new centers ramp up.